QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
QQQ   312.72 (+1.82%)
AAPL   160.77 (+1.98%)
MSFT   280.51 (+1.92%)
META   205.35 (+2.33%)
GOOGL   101.39 (+0.36%)
AMZN   100.25 (+3.10%)
TSLA   193.88 (+2.48%)
NVDA   269.84 (+2.17%)
NIO   9.83 (+6.85%)
BABA   99.92 (+1.54%)
AMD   96.09 (+1.62%)
T   19.00 (+1.50%)
F   12.05 (+3.88%)
MU   63.54 (+7.19%)
CGC   1.81 (+0.00%)
GE   94.06 (+0.99%)
DIS   96.87 (+2.16%)
AMC   5.00 (-2.91%)
PFE   40.25 (+0.65%)
PYPL   74.18 (+2.04%)
NFLX   332.03 (+2.63%)
NASDAQ:TXMD

TherapeuticsMD - TXMD Stock Forecast, Price & News

$3.54
+0.05 (+1.43%)
(As of 03/29/2023 12:00 AM ET)
Add
Compare
Today's Range
$3.47
$3.67
50-Day Range
$3.40
$5.49
52-Week Range
$1.99
$21.00
Volume
31,407 shs
Average Volume
43,449 shs
Market Capitalization
$33.35 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

TherapeuticsMD MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
2.98% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Selling Shares
$15,325 Sold Last Quarter
Proj. Earnings Growth
Decreasing
From $2.47 to ($0.79) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.93 out of 5 stars

Medical Sector

993rd out of 999 stocks

Pharmaceutical Preparations Industry

488th out of 489 stocks


TXMD stock logo

About TherapeuticsMD (NASDAQ:TXMD) Stock

TherapeuticsMD, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of products for women. The firm's technology, SYMBODA, develops advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. It also manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter vitamins under the BIJUVA, IMVEXXY, vitaMedMD and BocaGreenMD brands. The company was founded by Robert G. Finizio and Brian A. Bernick in 1907 and is headquartered in Boca Raton, FL.

Receive TXMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter.

TXMD Stock News Headlines

TheraputicsMD sells products rights for $153 million
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
My No. 1 dividend stock for a LIFETIME of income.
Few people realize this… But dividends account for up to 90% of the stock market's returns over the past century!  I think it's a crying shame folks don't know how powerful dividends are.
TherapeuticsMD Announces $7 Million Private Placement
See More Headlines
Receive TXMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for TherapeuticsMD and its competitors with MarketBeat's FREE daily newsletter.

TXMD Company Calendar

Last Earnings
11/11/2021
Today
3/29/2023
Next Earnings (Estimated)
3/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TXMD
Previous Symbol
NYSEMKT:TXMD
Employees
416
Year Founded
N/A

Profitability

Net Income
$-172,410,000.00
Pretax Margin
-9.57%

Debt

Sales & Book Value

Annual Sales
$86.95 million
Book Value
($11.05) per share

Miscellaneous

Free Float
8,596,000
Market Cap
$33.16 million
Optionable
Optionable
Beta
1.20

Key Executives

  • Marlan WalkerMarlan Walker
    Chief Executive Officer
  • Hugh O'Dowd
    President & Director
  • Daniella Silva
    Chief Compliance Officer
  • Douglas Mike Steelman
    Vice President-Market Access
  • Kevin McCabe
    Chief Exclusivity Officer













TXMD Stock - Frequently Asked Questions

Should I buy or sell TherapeuticsMD stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for TherapeuticsMD in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" TXMD shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TXMD, but not buy additional shares or sell existing shares.
View TXMD analyst ratings
or view top-rated stocks.

How have TXMD shares performed in 2023?

TherapeuticsMD's stock was trading at $5.59 at the beginning of the year. Since then, TXMD stock has decreased by 37.0% and is now trading at $3.52.
View the best growth stocks for 2023 here
.

When is TherapeuticsMD's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 30th 2023.
View our TXMD earnings forecast
.

How were TherapeuticsMD's earnings last quarter?

TherapeuticsMD, Inc. (NASDAQ:TXMD) announced its quarterly earnings results on Thursday, November, 11th. The company reported ($5.50) earnings per share for the quarter, missing analysts' consensus estimates of ($5.00) by $0.50. The business earned $25.41 million during the quarter, compared to analysts' expectations of $26.65 million. During the same quarter in the previous year, the business earned ($5.00) EPS.

When did TherapeuticsMD's stock split?

TherapeuticsMD shares reverse split on Monday, May 9th 2022. The 1-50 reverse split was announced on Monday, May 9th 2022. The number of shares owned by shareholders was adjusted after the market closes on Monday, May 9th 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

What other stocks do shareholders of TherapeuticsMD own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TherapeuticsMD investors own include OPKO Health (OPK), Verastem (VSTM), Teva Pharmaceutical Industries (TEVA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Gilead Sciences (GILD), Cleveland-Cliffs (CLF), Novavax (NVAX) and Micron Technology (MU).

What is TherapeuticsMD's stock symbol?

TherapeuticsMD trades on the NASDAQ under the ticker symbol "TXMD."

Who are TherapeuticsMD's major shareholders?

TherapeuticsMD's stock is owned by many different institutional and retail investors. Top institutional investors include Tejara Capital Ltd (3.37%), Simplex Trading LLC (0.00%), Morgan Stanley (1.42%), Susquehanna International Group LLP (0.00%), Group One Trading L.P. (0.00%) and Geode Capital Management LLC (0.71%). Insiders that own company stock include Brian Bernick, Cooper C Collins, Edward Borkowski, Gail K Naughton, James Darecca, Marlan D Walker, Marlan D Walker, Michael C Donegan, Michael C Donegan, Paul Bisaro, Robert G Finizio, Rubric Capital Management Lp, Tommy G Thompson and Tommy G Thompson.
View institutional ownership trends
.

How do I buy shares of TherapeuticsMD?

Shares of TXMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is TherapeuticsMD's stock price today?

One share of TXMD stock can currently be purchased for approximately $3.52.

How much money does TherapeuticsMD make?

TherapeuticsMD (NASDAQ:TXMD) has a market capitalization of $33.16 million and generates $86.95 million in revenue each year. The company earns $-172,410,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis.

How many employees does TherapeuticsMD have?

The company employs 416 workers across the globe.

How can I contact TherapeuticsMD?

TherapeuticsMD's mailing address is 951 Yamato Road Suite 220, BOCA RATON FL, 33431. The official website for the company is www.therapeuticsmd.com. The company can be reached via phone at (561) 961-1900, via email at shareholder@broadridge.com, or via fax at 561-431-3389.

This page (NASDAQ:TXMD) was last updated on 3/29/2023 by MarketBeat.com Staff